The impact of cytochrome P450 3A genetic polymorphisms on tacrolimus pharmacokinetics in ulcerative colitis patients
暂无分享,去创建一个
Toshio Watanabe | Y. Fujiwara | Y. Nadatani | K. Otani | S. Hosomi | Y. Nagami | F. Tanaka | N. Kamata | K. Taira | S. Fukunaga | Kenji Watanabe | Y. Nishida | Shigehiro Itani | Maizumi Furuse | Yuji Nadatani
[1] Y. Touitou,et al. Effect of CYP3A4*22 and CYP3A4*1B but not CYP3A5*3 polymorphisms on tacrolimus pharmacokinetic model in Tunisian kidney transplant , 2020, Toxicology and Applied Pharmacology.
[2] J. Fehr,et al. The Influence of Pharmacogenetic Variants in HIV/Tuberculosis Coinfected Patients in Uganda in the SOUTH Study , 2019, Clinical pharmacology and therapeutics.
[3] T. Hibi,et al. Individualized treatment based on CYP3A5 single-nucleotide polymorphisms with tacrolimus in ulcerative colitis , 2019, Intestinal research.
[4] A. Somogyi,et al. Effect of tacrolimus dispositional genetics on acute rejection in the first 2 weeks and estimated glomerular filtration rate in the first 3 months following kidney transplantation , 2019, Pharmacogenetics and genomics.
[5] Hailing Qiao,et al. Association of CYP3A4*1B genotype with Cyclosporin A pharmacokinetics in renal transplant recipients: A meta-analysis. , 2018, Gene.
[6] A. Spinelli,et al. Surgery in ulcerative colitis: When? How? , 2018, Best practice & research. Clinical gastroenterology.
[7] LiuFei,et al. Long-Term Influence of CYP3A5, CYP3A4, ABCB1, and NR1I2 Polymorphisms on Tacrolimus Concentration in Chinese Renal Transplant Recipients. , 2017 .
[8] T. Shimosegawa,et al. ATP‐binding cassette subfamily B member 1 1236C/T polymorphism significantly affects the therapeutic outcome of tacrolimus in patients with refractory ulcerative colitis , 2017, Journal of gastroenterology and hepatology.
[9] L. Peyrin-Biroulet,et al. Ulcerative colitis , 2017, The Lancet.
[10] M. Hirata,et al. Influence of ABCC2, CYP2C8, and CYP2J2 Polymorphisms on Tacrolimus and Mycophenolate Sodium–Based Treatment in Brazilian Kidney Transplant Recipients , 2017, Pharmacotherapy.
[11] O. Inatomi,et al. The effect of CYP3A5 genetic polymorphisms on adverse events in patients with ulcerative colitis treated with tacrolimus. , 2017, Digestive and liver disease : official journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver.
[12] Na Gao,et al. Physiological Content and Intrinsic Activities of 10 Cytochrome P450 Isoforms in Human Normal Liver Microsomes , 2016, The Journal of Pharmacology and Experimental Therapeutics.
[13] A. Ido,et al. Efficacy and Safety of Tacrolimus Therapy for Active Ulcerative Colitis; A Systematic Review and Meta-analysis. , 2016, Journal of Crohn's & colitis.
[14] Y. Tanigawara,et al. Impact of cytochrome P450 2C19 polymorphisms on the pharmacokinetics of tacrolimus when coadministered with voriconazole , 2015, Journal of clinical pharmacology.
[15] K. Aouam,et al. Influence of combined CYP3A4 and CYP3A5 single-nucleotide polymorphisms on tacrolimus exposure in kidney transplant recipients: a study according to the post-transplant phase. , 2015, Pharmacogenomics.
[16] A. Gayle,et al. Effect of Genetic Polymorphism of CYP3A5 and CYP2C19 and Concomitant Use of Voriconazole on Blood Tacrolimus Concentration in Patients Receiving Hematopoietic Stem Cell Transplantation , 2015, Therapeutic drug monitoring.
[17] M. Huang,et al. Interactive effects of CYP3A4, CYP3A5, MDR1 and NR1I2 polymorphisms on tracrolimus trough concentrations in early postrenal transplant recipients. , 2015, Pharmacogenomics.
[18] Julia M. Barbarino,et al. Clinical Pharmacogenetics Implementation Consortium (CPIC) Guidelines for CYP3A5 Genotype and Tacrolimus Dosing , 2015, Clinical pharmacology and therapeutics.
[19] Wei Zhang,et al. CYP3A4*1G Genetic Polymorphism Influences Metabolism of Fentanyl in Human Liver Microsomes in Chinese Patients , 2015, Pharmacology.
[20] K. Ohtsuka,et al. Tacrolimus for the Treatment of Ulcerative Colitis , 2015, Intestinal research.
[21] J. Qiu,et al. The effect of CYP3A4*1G allele on the pharmacokinetics of atorvastatin in Chinese han patients with coronary heart disease , 2014, Journal of clinical pharmacology.
[22] T. Matsui,et al. Impact of CYP3A5 genetic polymorphisms on the pharmacokinetics and short‐term remission in patients with ulcerative colitis treated with tacrolimus , 2014, Journal of gastroenterology and hepatology.
[23] S. Uemoto,et al. Influence of cytochrome P450 (CYP) 3A4*1G polymorphism on the pharmacokinetics of tacrolimus, probability of acute cellular rejection, and mRNA expression level of CYP3A5 rather than CYP3A4 in living-donor liver transplant patients. , 2013, Biological & pharmaceutical bulletin.
[24] M. Shimizu,et al. CYP3A4 intron 6 C>T polymorphism (CYP3A4*22) is associated with reduced CYP3A4 protein level and function in human liver microsomes. , 2013, The Journal of toxicological sciences.
[25] J. Barrett,et al. Effects of CYP3A4 and CYP3A5 polymorphisms on tacrolimus pharmacokinetics in Chinese adult renal transplant recipients: a population pharmacokinetic analysis , 2013, Pharmacogenetics and genomics.
[26] U. Christians,et al. Multidrug Resistance-Associated Protein 2 (MRP2/ABCC2) Haplotypes Significantly Affect the Pharmacokinetics of Tacrolimus in Kidney Transplant Recipients , 2013, Clinical Pharmacokinetics.
[27] Jie Lu,et al. Human PXR modulates hepatotoxicity associated with rifampicin and isoniazid co–therapy , 2013, Nature Medicine.
[28] G. Koren,et al. Tacrolimus-induced nephrotoxicity and genetic variability: a review. , 2012, Annals of transplantation.
[29] T. Habuchi,et al. Impact of the CYP3A4*1G polymorphism and its combination with CYP3A5 genotypes on tacrolimus pharmacokinetics in renal transplant patients. , 2011, Pharmacogenomics.
[30] Yuangan Wu,et al. Impact of CYP3A4*1G polymorphism on metabolism of fentanyl in Chinese patients undergoing lower abdominal surgery. , 2011, Clinica chimica acta; international journal of clinical chemistry.
[31] J. Qiu,et al. A functional polymorphism in the CYP3A4 gene is associated with increased risk of coronary heart disease in the Chinese Han population. , 2011, Basic & clinical pharmacology & toxicology.
[32] K. Verbeke,et al. Tacrolimus Dose Requirements and CYP3A5 Genotype and the Development of Calcineurin Inhibitor-Associated Nephrotoxicity in Renal Allograft Recipients , 2010, Therapeutic drug monitoring.
[33] T. Habuchi,et al. Impact of the CYP 3 A 4 * 1 G polymorphism and its combination with CYP 3 A 5 genotypes on tacrolimus pharmacokinetics in renal transplant patients , 2009 .
[34] J. Ellenberg,et al. Use of the noninvasive components of the mayo score to assess clinical response in Ulcerative Colitis , 2008, Inflammatory bowel diseases.
[35] B. Charpentier,et al. Influence of CYP3A5 genetic polymorphism on tacrolimus daily dose requirements and acute rejection in renal graft recipients. , 2008, Basic & clinical pharmacology & toxicology.
[36] Zheng Jiao,et al. Association of MDR1, CYP3A4*18B, and CYP3A5*3 polymorphisms with cyclosporine pharmacokinetics in Chinese renal transplant recipients , 2008, European Journal of Clinical Pharmacology.
[37] G. Tenderich,et al. No association between single nucleotide polymorphisms and the development of nephrotoxicity after orthotopic heart transplantation. , 2008, The Journal of heart and lung transplantation : the official publication of the International Society for Heart Transplantation.
[38] A. Griffiths,et al. Response to corticosteroids in severe ulcerative colitis: a systematic review of the literature and a meta-regression. , 2007, Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association.
[39] V. Haufroid,et al. CYP3A5 and ABCB1 Polymorphisms and Tacrolimus Pharmacokinetics in Renal Transplant Candidates: Guidelines from an Experimental Study , 2006, American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons.
[40] B. Vinet,et al. Cyp3A4, Cyp3A5, and MDR-1 genetic influences on tacrolimus pharmacokinetics in renal transplant recipients , 2006, Pharmacogenetics and genomics.
[41] J. Goldstein,et al. Functionally defective or altered CYP3A4 and CYP3A5 single nucleotide polymorphisms and their detection with genotyping tests. , 2005, Pharmacogenomics.
[42] R. Kim,et al. Genetic variability in CYP3A5 and its possible consequences. , 2004, Pharmacogenomics.
[43] T. Habuchi,et al. Influence of CYP3A5 and MDR1 (ABCB1) Polymorphisms on the Pharmacokinetics of Tacrolimus in Renal Transplant Recipients , 2004, Transplantation.
[44] S. Masuda,et al. CYP3A5*1-carrying graft liver reduces the concentration/oral dose ratio of tacrolimus in recipients of living-donor liver transplantation. , 2004, Pharmacogenetics.
[45] Teruhiko Yoshida,et al. Haplotypes of CYP3A4 and their close linkage with CYP3A5 haplotypes in a Japanese population , 2004, Human mutation.
[46] J. Hudson,et al. The human pregnane X receptor: genomic structure and identification and functional characterization of natural allelic variants. , 2001, Pharmacogenetics.
[47] Ann Daly,et al. Sequence diversity in CYP3A promoters and characterization of the genetic basis of polymorphic CYP3A5 expression , 2001, Nature Genetics.
[48] M. Lai,et al. Novel mutations of CYP3A4 in Chinese. , 2001, Drug metabolism and disposition: the biological fate of chemicals.
[49] H. Yamazaki,et al. Metabolism of FK506, a potent immunosuppressive agent, by cytochrome P450 3A enzymes in rat, dog and human liver microsomes. , 1994, Biochemical pharmacology.